U.S. Serial No.: 09/892,613 Filed : June 27, 2001

Page : 2

## Amendments to the claims

- 1. (Currently Amended) A re-engineered, or framework (FR)patched immunoglobulin containing the heavy and/or light chain variable region sequences from a parent antibody, in which at of the compartmentalized framework sequences, defined as FR1, FR2, FR3 and FR4 are replaced, or patched by the corresponding framework sequences from the heavy and light chain immunoglobulin variable region of a different species, wherein said re-engineered immunoglobulin chain(s) comprises framework sequences derived from at least two different sources of different immunoglobulin chains, wherein said different immunoglobulin chains can be sourced from different immunoglobulins of the same species or from immunoglobulins of different species, and such FR-patched immunoglobulin binds specifically to an antigen with affinity comparable to within ten-fold, or within 3-fold of, that of the parent immunoglobulin with the proviso that not all the replaced FR1, FR2, FR3 and FR4 are from the same framework of a single immunoglobulin chain.
- 2. (Previously presented) A re-engineered, or FR-patched immunoglobulin according to claim 1, in which the particular FR chosen for patching or replacing each corresponding FR in the parent immunoglobulin:
  - a. exhibits the highest degree of homology, or at least 60%, to the corresponding parent FR;
  - b. exhibits identical sequence homology to the corresponding parent FR at the three amino acids immediately adjacent to the flanking CDR's; and
  - c. contains identical amino acid to the corresponding parent FR at positions known to be close to, or have interactions with the CDR's/antigen binding site, as evaluated by computer modeling, crystal structure, published information, or prior experience.

U.S. Serial No.: 09/892,613 Filed : June 27, 2001

Page : 3

- 3. (Original) A re-engineered, or FR-patched immunoglobulin according to claim 1, in which the particular FR chosen for patching or replacing each corresponding FR in the parent immunoglobulin:
  - a. exhibits the highest degree of homology, or at least 60%, to the corresponding parent FR;
  - b. exhibits identical sequence homology to the corresponding parent FR at the four amino acids immediately adjacent to the flanking CDR's; and
  - c. contains identical amino acid to the corresponding parent FR at positions known to be close to, or have interactions with the CDR's/antigen binding site, as evaluated by computer modeling, crystal structure, published information, or prior experience.
- 4. (Currently Amended) A re-engineered, or FR-patched immunoglobulin according to claim 1, in which the particular FR chosen for patching or replacing each corresponding FR in the parent immunoglobulin:
  - exhibits the highest degree of homology, or at least
    60%, to the corresponding parent FR;
  - b. exhibits the highest degree of sequence homology to the corresponding parent FR, preferably 100% identical, or contains conservatively similar amino acids, such as, gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr, at the three amino acids immediately adjacent to the flanking CDR's; and
  - c. contains identical, or conservatively similar amino acids (as listed in claim 4b) to the corresponding parent FR at positions known to be close to, or have interactions with the CDR's/antigen binding site, as

Applicants : LEUNG, Shawn Shui-on U.S. Serial No.: 09/892,613

U.S. Serial No.: 09/892,613 Filed : June 27, 2001

Page : 4

evaluated by computer modeling, crystal structure, published information, or prior experience.

- 5. (Currently Amended) A re-engineered, or FR-patched immunoglobulin according to claim 1, in which the particular FR chosen for patching each corresponding FR in the parent immunoglobulin:
  - a. exhibits the highest degree of homology, or at least 60%, to the corresponding parent FR;
  - b. exhibits the highest degree of sequence homology to the corresponding parent FR, preferably 100% identical, or contains conservatively similar amino acids (as listed in claim 4b) at the four amino acids immediately adjacent to the flanking CDR's; and
  - c. contains identical, or conservatively similar amino acids (as listed in claim 4b) to the corresponding parent FR at positions known to be close to, or have interactions with the CDR's/antigen binding site, as evaluated by computer modeling, crystal structure, published information, or prior experience.
- 6. (Currently Amended) A re-engineered, or FR-patched immunoglobulin according to claim 1, 2, 3, 4 or 5 containing the heavy and/or light chain variable region sequences from a parent antibody, in which the particular FR patching each corresponding FR in the parent immunoglobulin comprises re-introduced amino acids from the parent immunoglobulin framework outside the Kabat and Chothia CDRs, wherein the back mutated re-introduced amino acids replace corresponding amino acids in the patching FR , which is the particular FR derived from a different source used for patching, or that replaces the original FR of, the parent

U.S. Serial No.: 09/892,613

Filed : June 27, 2001

Page : 5

immunoglobulin, and each of said back mutated re-introduced amino acids:

- a. is adjacent to a CDR in the donor immunoglobulin sequence, or
- b. contains an atom within a distance of 4 Å of a CDR in said re-engineered immunoglobulin.
- (Currently Amended) A re-engineered, or FR-patched immunoglobulin according to claim 1, 2, 3, 4 or 5 containing the heavy and/or light chain variable region sequences from a parent antibody, in which the particular FR chosen for patching each corresponding FR in the parent immunoglobulin comprises re-introduced amino acids from immunoglobulin framework outside the Kabat and Chothia CDRs, wherein the back mutated re-introduced amino acids replace corresponding amino acids in the patching FR, which is the particular FR derived from a different source used for patching, or that replaces the original FR of, the parent immunoglobulin, and each of said back mutated re-introduced amino acids:
  - a. is adjacent to a CDR in the donor immunoglobulin sequence, or
  - b. contains an atom within a distance of 5 Å of a CDR in said re-engineered immunoglobulin.
- 8. (Currently Amended) A re-engineered, or FR-patched immunoglobulin according to claim 1, 2, 3, 4 or 5 containing the heavy and/or light chain variable region sequences from a parent antibody, in which the particular FR chosen for patching each corresponding FR in the parent immunoglobulin comprises re-introduced amino acids from the parent immunoglobulin framework outside the Kabat and Chothia CDRs, wherein the back mutated re-introduced amino acids replace

U.S. Serial No.: 09/892,613 Filed : June 27, 2001

Page : 6

corresponding amino acids in the patching FR, which is the particular FR derived from a different source used for patching, or that replaces the original FR of, the parent immunoglobulin, and each of said back mutated re-introduced amino acids:

- a. is adjacent to a CDR in the donor immunoglobulin sequence, or
- b. contains an atom within a distance of 6 Å of a CDR in said re-engineered immunoglobulin.
- 9. (Currently Amended) A re-engineered, or FR-patched immunoglobulin according to claim 1, 2, 3, 4 or 5 containing the heavy and/or light chain variable region sequences from a parent antibody, in which the particular FR chosen for patching each corresponding FR in the parent immunoglobulin comprises re-introduced amino acids from the immunoglobulin framework outside the Kabat and Chothia CDRs, wherein the back mutated re-introduced amino acids replace corresponding amino acids in the patching FR, which is the particular FR derived from a different source used for patching, or that replaces the original FR of, the parent immunoglobulin, and each of said back mutated re-introduced amino acids:
  - a. is adjacent to a CDR in the donor immunoglobulin sequence, or
  - b. is capable of interacting with amino acids in the CDRs, or
  - c. is typical at its position for the species of the particular FR chosen for the patching, and the replaced amino acid in the said FR is rare at its position for the species from where the FR is derived.

U.S. Serial No.: 09/892,613 Filed : June 27, 2001

Page : 7

- 10. (Previously presented) A re-engineered, or FR-patched immunoglobulin according to claim 1, 2, 3, 4, 5, 6, 7, 8, or 9, which specifically binds to an antigen with an affinity of between  $10^7 \, \text{M}^{-1}$  and  $10^{11} \, \text{M}^{-1}$ .
- 11. (Previously presented) A re-engineered, or FR-patched immunoglobulin according to claim 1, 2, 3, 4, 5, 6, 7, 8, or 9, which specifically binds to an antigen with an affinity of between  $10^8 \, \text{M}^{-1}$  and  $10^{10} \, \text{M}^{-1}$ .
- 12. (Previously presented) A re-engineered, or FR-patched immunoglobulin according to claim 1, 2, 3, 4, 5, 6, 7, 8, or 9 which is substantially pure.
- 13. (Previously presented) A pharmaceutical composition comprising a re-engineered, or FR-patched immunoglobulin according to claim 1, 2, 3, 4, 5, 6, 7, 8, or 9 in a pharmaceutically acceptable carrier.
- 14. (Original) A method of constructing a re-engineered, or FR-patched immunoglobulin according to claim 1, 2, 3, 4, 5, 6, 7, 8, and 9 that will reduce the percentage of amino acid sequences derived from the parent immunoglobulin.
- 15. (Original) A method of constructing a re-engineered, or FR-patched immunoglobulin according to claim 1, 2, 3, 4, 5, 6, 7, 8, and 9 that will reduce the immunogenicity of the reengineered, or FR-patched immunoglobulin, when used in the intended species (for example human), compared to that of the parent immunoglobulin.
- 16. 19. (Cancelled)